Amgen Stock Forecast, Price & News

25 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last year. There are currently 2 sell ratings, 9 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Amgen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View analyst ratings for Amgen or view top-rated stocks.

Wall Street analysts have given Amgen a "Hold" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Amgen wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Amgen.

Amgen will be holding an earnings conference call on Tuesday, August 3rd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link or dial in at 404-537-3406 with passcode "1682169".

Amgen Inc. (NASDAQ:AMGN) issued its quarterly earnings data on Monday, April, 26th. The medical research company reported $3.70 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $4.05 by $0.35. The medical research company earned $5.90 billion during the quarter, compared to analysts' expectations of $6.30 billion. Amgen had a net margin of 28.16% and a trailing twelve-month return on equity of 93.84%. The business's revenue for the quarter was down 4.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted $4.17 earnings per share.
View Amgen's earnings history.

Amgen's stock was trading at $198.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, AMGN shares have increased by 23.4% and is now trading at $245.08.
View which stocks have been most impacted by COVID-19.

Amgen declared a quarterly dividend on Wednesday, March 3rd. Investors of record on Monday, May 17th will be given a dividend of $1.76 per share on Tuesday, June 8th. This represents a $7.04 annualized dividend and a dividend yield of 2.87%. The ex-dividend date is Friday, May 14th.
View Amgen's dividend history.

Amgen pays an annual dividend of $7.04 per share and currently has a dividend yield of 2.84%. Amgen does not yet have a strong track record of dividend growth. The dividend payout ratio of Amgen is 42.41%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Amgen will have a dividend payout ratio of 39.09% next year. This indicates that Amgen will be able to sustain or increase its dividend.
View Amgen's dividend history.

Amgen issued an update on its FY 2021 earnings guidance on Tuesday, May, 4th. The company provided earnings per share guidance of 16.000-17.000 for the period, compared to the Thomson Reuters consensus EPS estimate of $16.800. The company issued revenue guidance of $25.80 billion-$26.60 billion, compared to the consensus revenue estimate of $26.41 billion.

25 Wall Street analysts have issued twelve-month target prices for Amgen's shares. Their forecasts range from $200.00 to $301.00. On average, they expect Amgen's share price to reach $256.19 in the next year. This suggests a possible upside of 4.5% from the stock's current price.
View analysts' price targets for Amgen or view top-rated stocks among Wall Street analysts.

806 employees have rated Amgen CEO Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among Amgen's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Amgen include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Exact Sciences (EXAS), Incyte (INCY), Novavax (NVAX), BioMarin Pharmaceutical (BMRN), Repligen (RGEN), Neurocrine Biosciences (NBIX), United Therapeutics (UTHR) and Halozyme Therapeutics (HALO).
View all of AMGN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), The Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and The Home Depot (HD).

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Amgen's stock is owned by a number of institutional and retail investors. Top institutional shareholders include State of Alaska Department of Revenue (0.02%), Oregon Public Employees Retirement Fund (0.02%), Alpha Cubed Investments LLC (0.02%), IFM Investors Pty Ltd (0.01%), Compagnie Lombard Odier SCmA (0.01%) and Palisade Asset Management LLC (0.01%). Company insiders that own Amgen stock include Cynthia M Patton, David Piacquad, David W Meline, Jonathan P Graham, Nancy A Grygiel, R Sanders Williams and Ronald D Sugar.
View institutional ownership trends for Amgen.

AMGN stock was sold by a variety of institutional investors in the last quarter, including Compagnie Lombard Odier SCmA, Raymond James Trust N.A., Taylor Cottrill Erickson & Associates Inc., Alpha Cubed Investments LLC, Access Financial Services Inc., Sitrin Capital Management LLC, Fulton Bank N.A., and Stock Yards Bank & Trust Co.. Company insiders that have sold Amgen company stock in the last year include Jonathan P Graham, Nancy A Grygiel, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen or view top insider-selling stocks.

AMGN stock was bought by a variety of institutional investors in the last quarter, including Transform Wealth LLC, IFM Investors Pty Ltd, Oregon Public Employees Retirement Fund, Brookstone Capital Management, LaFleur & Godfrey LLC, New England Research & Management Inc., CHICAGO TRUST Co NA, and Gradient Investments LLC.
View insider buying and selling activity for Amgen or or view top insider-buying stocks.

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AMGN stock can currently be purchased for approximately $245.08.

Amgen has a market capitalization of $140.81 billion and generates $25.42 billion in revenue each year. The medical research company earns $7.26 billion in net income (profit) each year or $16.60 on an earnings per share basis.

Amgen employs 24,300 workers across the globe.

The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen (Europe) GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen Manufacturing Limited, Amgen Research (Munich) GmbH, Amgen Rockville Inc., Amgen S.A.S., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology (Ireland) Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Synergen, and Tularik.

Amgen was founded in 1980.

The official website for Amgen is www.amgen.com.

Amgen is headquartered at ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320.

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at (805) 447-1000 or via email at [email protected]com.